CTI BioPharma
Quick facts
Phase 3 pipeline
- Gemcitabine + Rituximab · Oncology
Gemcitabine damages cancer cell DNA while rituximab targets and eliminates B cells expressing CD20, combining chemotherapy with immunotherapy. - pixantrone, cyclophosphamide, vincristine, rituximab, prednisone · Oncology
Pixantrone is a synthetic anthracenedione that intercalates DNA, thereby inhibiting DNA replication and transcription. - Pixantrone + Rituximab · Oncology
Pixantrone is a topoisomerase II inhibitor that damages cancer cell DNA, combined with rituximab, a CD20-targeting monoclonal antibody that depletes B cells.
Phase 2 pipeline
- CHOP-R · Oncology
CHOP-R is a chemotherapy regimen that combines rituximab with a modified version of the CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine, and prednisone. - CHR-2797
- CPOP-R
- CT-2106 · Oncology
CT-2106 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
Phase 1 pipeline
- A: pacritinib · Oncology
JAK2 inhibitor - C: moxifloxacin
- Pacritinib and Clarithromycin
- Pacritinib and Rifampin
- Pixantrone IV infusion
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: